Maternal use of acetaminophen during pregnancy and risk of autism spectrum disorders in childhood: A Danish national birth cohort study / Zeyan LIEW in Autism Research, 9-9 (September 2016)  

Public ISBD [article]  inAutism Research > 9-9 (September 2016) . - p.951-958 Titre : Maternal use of acetaminophen during pregnancy and risk of autism spectrum disorders in childhood: A Danish national birth cohort study Type de document : Texte imprimé et/ou numérique Auteurs : Zeyan LIEW, Auteur ; Beate RITZ, Auteur ; Jasveer VIRK, Auteur ; Jørn OLSEN, Auteur Article en page(s) : p.951-958 Langues : Anglais (eng) Mots-clés : acetaminophen  autism spectrum disorders  infantile autism  childhood behavior  prenatal exposure  pregnancy cohort Index. décimale : PER Périodiques Résumé : Acetaminophen (paracetamol) is the most commonly used pain and fever medication during pregnancy. Previously, a positive ecological correlation between acetaminophen use and autism spectrum disorders (ASD) has been reported but evidence from larger studies based on prospective data is lacking. We followed 64,322 children and mothers enrolled in the Danish National Birth Cohort (DNBC; 1996–2002) for average 12.7 years to investigate whether acetaminophen use in pregnancy is associated with increased risk of ASD in the offspring. Information on acetaminophen use was collected prospectively from three computer-assisted telephone interviews. We used records from the Danish hospital and psychiatric registries to identify diagnoses of ASD. At the end of follow up, 1,027 (1.6%) children were diagnosed with ASD, 345 (0.5%) with infantile autism. We found that 31% of ASD (26% of infantile autism) have also been diagnosed with hyperkinetic disorders. More than 50% women reported ever using acetaminophen in pregnancy. We used Cox proportional hazards model to estimate hazard ratio (HR) and 95% confident interval (CI). Prenatal use of acetaminophen was associated with an increased risk of ASD accompanied by hyperkinetic symptoms (HR?=?1.51 95% CI 1.19–1.92), but not with other ASD cases (HR?=?1.06 95% CI 0.92–1.24). Longer duration of use (i.e., use for >20 weeks in gestation) increased the risk of ASD or infantile autism with hyperkinetic symptoms almost twofold. Maternal use of acetaminophen in pregnancy was associated with ASD with hyperkinetic symptoms only, suggesting acetaminophen exposure early in fetal life may specifically impact this hyperactive behavioral phenotype. Autism Res 2016, 9: 951–958. En ligne : http://dx.doi.org/10.1002/aur.1591 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=294 [article] Maternal use of acetaminophen during pregnancy and risk of autism spectrum disorders in childhood: A Danish national birth cohort study [Texte imprimé et/ou numérique] / Zeyan LIEW, Auteur ; Beate RITZ, Auteur ; Jasveer VIRK, Auteur ; Jørn OLSEN, Auteur . - p.951-958. Langues : Anglais (eng) in Autism Research > 9-9 (September 2016) . - p.951-958 Mots-clés : acetaminophen  autism spectrum disorders  infantile autism  childhood behavior  prenatal exposure  pregnancy cohort Index. décimale : PER Périodiques Résumé : Acetaminophen (paracetamol) is the most commonly used pain and fever medication during pregnancy. Previously, a positive ecological correlation between acetaminophen use and autism spectrum disorders (ASD) has been reported but evidence from larger studies based on prospective data is lacking. We followed 64,322 children and mothers enrolled in the Danish National Birth Cohort (DNBC; 1996–2002) for average 12.7 years to investigate whether acetaminophen use in pregnancy is associated with increased risk of ASD in the offspring. Information on acetaminophen use was collected prospectively from three computer-assisted telephone interviews. We used records from the Danish hospital and psychiatric registries to identify diagnoses of ASD. At the end of follow up, 1,027 (1.6%) children were diagnosed with ASD, 345 (0.5%) with infantile autism. We found that 31% of ASD (26% of infantile autism) have also been diagnosed with hyperkinetic disorders. More than 50% women reported ever using acetaminophen in pregnancy. We used Cox proportional hazards model to estimate hazard ratio (HR) and 95% confident interval (CI). Prenatal use of acetaminophen was associated with an increased risk of ASD accompanied by hyperkinetic symptoms (HR?=?1.51 95% CI 1.19–1.92), but not with other ASD cases (HR?=?1.06 95% CI 0.92–1.24). Longer duration of use (i.e., use for >20 weeks in gestation) increased the risk of ASD or infantile autism with hyperkinetic symptoms almost twofold. Maternal use of acetaminophen in pregnancy was associated with ASD with hyperkinetic symptoms only, suggesting acetaminophen exposure early in fetal life may specifically impact this hyperactive behavioral phenotype. Autism Res 2016, 9: 951–958. En ligne : http://dx.doi.org/10.1002/aur.1591 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=294

Preconceptional and prenatal supplementary folic acid and multivitamin intake and autism spectrum disorders / Jasveer VIRK in Autism, 20-6 (August 2016)  

Public ISBD [article]  inAutism > 20-6 (August 2016) . - p.710-718 Titre : Preconceptional and prenatal supplementary folic acid and multivitamin intake and autism spectrum disorders Type de document : Texte imprimé et/ou numérique Auteurs : Jasveer VIRK, Auteur ; Zeyan LIEW, Auteur ; Jørn OLSEN, Auteur ; Ellen A NOHR, Auteur ; Janet M CATOV, Auteur ; Beate RITZ, Auteur Article en page(s) : p.710-718 Langues : Anglais (eng) Mots-clés : autism spectrum disorders  environmental factors Index. décimale : PER Périodiques Résumé : Objective: To evaluate whether early folic acid supplementation during pregnancy prevents diagnosis of autism spectrum disorders in offspring.Methods: Information on autism spectrum disorder diagnosis was obtained from the National Hospital Register and the Central Psychiatric Register. We estimated risk ratios for autism spectrum disorders for children whose mothers took folate or multivitamin supplements from 4?weeks prior from the last menstrual period through to 8?weeks after the last menstrual period (?4 to 8?weeks) by three 4-week periods.Results: We did not find an association between early folate or multivitamin intake for autism spectrum disorder (folic acid—adjusted risk ratio: 1.06, 95% confidence interval: 0.82–1.36; multivitamin—adjusted risk ratio: 1.00, 95% confidence interval: 0.82–1.22), autistic disorder (folic acid—adjusted risk ratio: 1.18, 95% confidence interval: 0.76–1.84; multivitamin—adjusted risk ratio: 1.22, 95% confidence interval: 0.87–1.69), Asperger’s syndrome (folic acid—adjusted risk ratio: 0.85, 95% confidence interval: 0.46–1.53; multivitamin—adjusted risk ratio: 0.95, 95% confidence interval: 0.62–1.46), or pervasive developmental disorder–not otherwise specified (folic acid—adjusted risk ratio: 1.07, 95% confidence interval: 0.75–1.54; multivitamin: adjusted risk ratio: 0.87, 95% confidence interval: 0.65–1.17) compared with women reporting no supplement use in the same period.Conclusion: We did not find any evidence to corroborate previous reports of a reduced risk for autism spectrum disorders in offspring of women using folic acid supplements in early pregnancy. En ligne : http://dx.doi.org/10.1177/1362361315604076 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=290 [article] Preconceptional and prenatal supplementary folic acid and multivitamin intake and autism spectrum disorders [Texte imprimé et/ou numérique] / Jasveer VIRK, Auteur ; Zeyan LIEW, Auteur ; Jørn OLSEN, Auteur ; Ellen A NOHR, Auteur ; Janet M CATOV, Auteur ; Beate RITZ, Auteur . - p.710-718. Langues : Anglais (eng) in Autism > 20-6 (August 2016) . - p.710-718 Mots-clés : autism spectrum disorders  environmental factors Index. décimale : PER Périodiques Résumé : Objective: To evaluate whether early folic acid supplementation during pregnancy prevents diagnosis of autism spectrum disorders in offspring.Methods: Information on autism spectrum disorder diagnosis was obtained from the National Hospital Register and the Central Psychiatric Register. We estimated risk ratios for autism spectrum disorders for children whose mothers took folate or multivitamin supplements from 4?weeks prior from the last menstrual period through to 8?weeks after the last menstrual period (?4 to 8?weeks) by three 4-week periods.Results: We did not find an association between early folate or multivitamin intake for autism spectrum disorder (folic acid—adjusted risk ratio: 1.06, 95% confidence interval: 0.82–1.36; multivitamin—adjusted risk ratio: 1.00, 95% confidence interval: 0.82–1.22), autistic disorder (folic acid—adjusted risk ratio: 1.18, 95% confidence interval: 0.76–1.84; multivitamin—adjusted risk ratio: 1.22, 95% confidence interval: 0.87–1.69), Asperger’s syndrome (folic acid—adjusted risk ratio: 0.85, 95% confidence interval: 0.46–1.53; multivitamin—adjusted risk ratio: 0.95, 95% confidence interval: 0.62–1.46), or pervasive developmental disorder–not otherwise specified (folic acid—adjusted risk ratio: 1.07, 95% confidence interval: 0.75–1.54; multivitamin: adjusted risk ratio: 0.87, 95% confidence interval: 0.65–1.17) compared with women reporting no supplement use in the same period.Conclusion: We did not find any evidence to corroborate previous reports of a reduced risk for autism spectrum disorders in offspring of women using folic acid supplements in early pregnancy. En ligne : http://dx.doi.org/10.1177/1362361315604076 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=290

Untargeted Metabolomics Screen of Mid-pregnancy Maternal Serum and Autism in Offspring / Beate RITZ in Autism Research, 13-8 (August 2020)  

Public ISBD [article]  inAutism Research > 13-8 (August 2020) . - p.1258-1269 Titre : Untargeted Metabolomics Screen of Mid-pregnancy Maternal Serum and Autism in Offspring Type de document : Texte imprimé et/ou numérique Auteurs : Beate RITZ, Auteur ; Qi YAN, Auteur ; Karan UPPAL, Auteur ; Zeyan LIEW, Auteur ; Xin CUI, Auteur ; Chenxiao LING, Auteur ; Kosuke INOUE, Auteur ; Ondine VON EHRENSTEIN, Auteur ; Douglas I. WALKER, Auteur ; Dean P. JONES, Auteur Article en page(s) : p.1258-1269 Langues : Anglais (eng) Mots-clés : autism  high-resolution metabolomics  mid-pregnancy serum  steroid hormones Index. décimale : PER Périodiques Résumé : Discovering pathophysiologic networks in a blood-based approach may help to generate valuable tools for early treatment or preventive measures in autism. To date targeted or untargeted metabolomics approaches to identify metabolic features and pathways affecting fetal neurodevelopment have rarely been applied to pregnancy samples, that is, an early period potentially relevant for the development of autism spectrum disorders (ASD). We conducted a population-based study relying on autism diagnoses retrieved from California Department of Developmental Services record. After linking cases to and sampling controls from birth certificates, we retrieved stored maternal mid-pregnancy serum samples collected as part of the California Prenatal Screening Program from the California Biobank for children born 2004 to 2010 in the central valley of California. We retrieved serum for 52 mothers whose children developed autism and 62 population controls originally selected from all eligible children matched by birth year and child's sex. Also, we required that these mothers were relatively low or unexposed to air pollution and select pesticides during early pregnancy. We identified differences in metabolite levels in several metabolic pathways, including glycosphingolipid biosynthesis and metabolism, N-glycan and pyrimidine metabolism, bile acid pathways and, importantly, C21-steroid hormone biosynthesis and metabolism. Disturbances in these pathways have been shown to be relevant for neurodevelopment in rare genetic syndromes or implicated in previous studies of autism. This study provides new insight into maternal mid-pregnancy metabolic features possibly related to the development of autism and an incentive to explore whether these pathways and metabolites are useful for early diagnosis, treatment, or prevention. LAY SUMMARY: This study found that in mid-pregnancy the blood of mothers who give birth to a child that develops autism has some characteristic features that are different from those of blood samples taken from control mothers. These features are related to biologic mechanisms that can affect fetal brain development. In the future, these insights may help identify biomarkers for early autism diagnosis and treatment or preventive measures. Autism Res 2020, 13: 1258-1269. © 2020 International Society for Autism Research, Wiley Periodicals, Inc. En ligne : http://dx.doi.org/10.1002/aur.2311 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=430 [article] Untargeted Metabolomics Screen of Mid-pregnancy Maternal Serum and Autism in Offspring [Texte imprimé et/ou numérique] / Beate RITZ, Auteur ; Qi YAN, Auteur ; Karan UPPAL, Auteur ; Zeyan LIEW, Auteur ; Xin CUI, Auteur ; Chenxiao LING, Auteur ; Kosuke INOUE, Auteur ; Ondine VON EHRENSTEIN, Auteur ; Douglas I. WALKER, Auteur ; Dean P. JONES, Auteur . - p.1258-1269. Langues : Anglais (eng) in Autism Research > 13-8 (August 2020) . - p.1258-1269 Mots-clés : autism  high-resolution metabolomics  mid-pregnancy serum  steroid hormones Index. décimale : PER Périodiques Résumé : Discovering pathophysiologic networks in a blood-based approach may help to generate valuable tools for early treatment or preventive measures in autism. To date targeted or untargeted metabolomics approaches to identify metabolic features and pathways affecting fetal neurodevelopment have rarely been applied to pregnancy samples, that is, an early period potentially relevant for the development of autism spectrum disorders (ASD). We conducted a population-based study relying on autism diagnoses retrieved from California Department of Developmental Services record. After linking cases to and sampling controls from birth certificates, we retrieved stored maternal mid-pregnancy serum samples collected as part of the California Prenatal Screening Program from the California Biobank for children born 2004 to 2010 in the central valley of California. We retrieved serum for 52 mothers whose children developed autism and 62 population controls originally selected from all eligible children matched by birth year and child's sex. Also, we required that these mothers were relatively low or unexposed to air pollution and select pesticides during early pregnancy. We identified differences in metabolite levels in several metabolic pathways, including glycosphingolipid biosynthesis and metabolism, N-glycan and pyrimidine metabolism, bile acid pathways and, importantly, C21-steroid hormone biosynthesis and metabolism. Disturbances in these pathways have been shown to be relevant for neurodevelopment in rare genetic syndromes or implicated in previous studies of autism. This study provides new insight into maternal mid-pregnancy metabolic features possibly related to the development of autism and an incentive to explore whether these pathways and metabolites are useful for early diagnosis, treatment, or prevention. LAY SUMMARY: This study found that in mid-pregnancy the blood of mothers who give birth to a child that develops autism has some characteristic features that are different from those of blood samples taken from control mothers. These features are related to biologic mechanisms that can affect fetal brain development. In the future, these insights may help identify biomarkers for early autism diagnosis and treatment or preventive measures. Autism Res 2020, 13: 1258-1269. © 2020 International Society for Autism Research, Wiley Periodicals, Inc. En ligne : http://dx.doi.org/10.1002/aur.2311 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=430

---

1 (1 - 3 / 3)